Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators. Lewis EF, et al. Among authors: young jb. Eur J Heart Fail. 2007 Jan;9(1):83-91. doi: 10.1016/j.ejheart.2006.10.012. Epub 2006 Dec 21. Eur J Heart Fail. 2007. PMID: 17188020 Free article.
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Young JB, et al. Circulation. 2004 Oct 26;110(17):2618-26. doi: 10.1161/01.CIR.0000146819.43235.A9. Epub 2004 Oct 18. Circulation. 2004. PMID: 15492298 Clinical Trial.
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
O'Meara E, Solomon S, McMurray J, Pfeffer M, Yusuf S, Michelson E, Granger C, Olofsson B, Young JB, Swedberg K. O'Meara E, et al. Among authors: young jb. Eur Heart J. 2004 Nov;25(21):1920-6. doi: 10.1016/j.ehj.2004.07.025. Eur Heart J. 2004. PMID: 15522471 Clinical Trial.
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
O'Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Ostergren J, Carlsson J, Olofsson B, McMurray J, Yusuf S, Swedberg K, Pfeffer MA. O'Meara E, et al. Among authors: young jb. Eur J Heart Fail. 2005 Jun;7(4):650-6. doi: 10.1016/j.ejheart.2005.01.021. Eur J Heart Fail. 2005. PMID: 15921807 Free article.
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S. Ducharme A, et al. Among authors: young jb. Am Heart J. 2006 May;151(5):985-91. doi: 10.1016/j.ahj.2005.06.036. Am Heart J. 2006. PMID: 16644318
Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators. McMurray JJ, et al. Among authors: young jb. Am Heart J. 2006 May;151(5):985-91. doi: 10.1016/j.ahj.2006.02.028. Am Heart J. 2006. PMID: 16644319
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators. Ducharme A, et al. Among authors: young jb. Am Heart J. 2006 Jul;152(1):86-92. Am Heart J. 2006. PMID: 16838426
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Solomon SD, et al. Among authors: young jb. Circulation. 2007 Sep 25;116(13):1482-7. doi: 10.1161/CIRCULATIONAHA.107.696906. Epub 2007 Aug 27. Circulation. 2007. PMID: 17724259
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA; CHARM Program Investigators. Desai AS, et al. Among authors: young jb. J Am Coll Cardiol. 2007 Nov 13;50(20):1959-66. doi: 10.1016/j.jacc.2007.07.067. Epub 2007 Oct 29. J Am Coll Cardiol. 2007. PMID: 17996561 Free article.
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators. MacDonald MR, et al. Among authors: young jb. Eur Heart J. 2008 Jun;29(11):1377-85. doi: 10.1093/eurheartj/ehn153. Epub 2008 Apr 14. Eur Heart J. 2008. PMID: 18413309 Clinical Trial.
786 results